168 related articles for article (PubMed ID: 38687753)
1. The association of EGFR amplification with aberrant exon 20 insertion report using the cobas EGFR Mutation Test v2.
Zhang MS; Yeh YC; Huang HN; Lin LW; Huang YL; Wang LC; Yao LJ; Hung TC; Tseng YF; Lee YH; Liao WY; Shih JY; Hsieh MS
PLoS One; 2024; 19(4):e0301120. PubMed ID: 38687753
[TBL] [Abstract][Full Text] [Related]
2. Lung adenocarcinoma with EGFR L858R-K860I and L858R-L861F doublet mutations from which the L858R mutation is undetectable through the cobas EGFR mutation test v2.
Wu CH; Zhang MS; Huang YL; Cheng WH; Lai JY; Hsieh MS; Liao WY
Pathol Res Pract; 2024 May; 257():155304. PubMed ID: 38657557
[TBL] [Abstract][Full Text] [Related]
3. Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer.
Geng D; Guo Q; Huang S; Zhang H; Guo S; Li X
Clin Transl Oncol; 2022 Feb; 24(2):379-387. PubMed ID: 34453698
[TBL] [Abstract][Full Text] [Related]
4. Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions.
Chen K; Pan G; Cheng G; Zhang F; Xu Y; Huang Z; Fan Y
Thorac Cancer; 2021 Jan; 12(2):218-226. PubMed ID: 33210451
[TBL] [Abstract][Full Text] [Related]
5. First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review.
Han H; Zhang X; Liu X; Zhao J; Zhang J; Zhang J; Zhu H; Jiao S; Tang H
Medicine (Baltimore); 2023 Dec; 102(52):e36667. PubMed ID: 38206746
[TBL] [Abstract][Full Text] [Related]
6. Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer.
Evrard SM; Taranchon-Clermont E; Rouquette I; Murray S; Dintner S; Nam-Apostolopoulos YC; Bellosillo B; Varela-Rodriguez M; Nadal E; Wiedorn KH; Melchior L; Andrew E; Jones M; Ridgway J; Frykman C; Lind L; Rot M; Kern I; Speel EJM; Roemen GMJM; Trincheri N; Freiberger SN; Rechsteiner M
J Mol Diagn; 2019 Nov; 21(6):1010-1024. PubMed ID: 31445213
[TBL] [Abstract][Full Text] [Related]
7. Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets.
Viteri S; Minchom A; Bazhenova L; Ou SI; Bauml JM; Shell SA; Schaffer M; Gu J; Rose JB; Curtin JC; Mahadevia P; Girard N
Mol Oncol; 2023 Feb; 17(2):230-237. PubMed ID: 36269676
[TBL] [Abstract][Full Text] [Related]
8. Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer.
O'Donnell P; Ferguson J; Shyu J; Current R; Rehage T; Tsai J; Christensen M; Tran HB; Chien SS; Shieh F; Wei W; Lawrence HJ; Wu L; Schilling R; Bloom K; Maltzman W; Anderson S; Soviero S
BMC Cancer; 2013 Apr; 13():210. PubMed ID: 23621958
[TBL] [Abstract][Full Text] [Related]
9. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
Yang GJ; Li J; Xu HY; Sun Y; Liu L; Li HS; Yang L; Zhang Y; Li GH; Wang Y
Lung Cancer; 2021 Feb; 152():39-48. PubMed ID: 33341538
[TBL] [Abstract][Full Text] [Related]
10. Detection of Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma: Comparing Cobas 4800 EGFR Assay With Sanger Bidirectional Sequencing.
Ardakani NM; Giardina T; Grieu-Iacopetta F; Tesfai Y; Carrello A; Taylor J; Robinson C; Spagnolo D; Amanuel B
Clin Lung Cancer; 2016 Sep; 17(5):e113-e119. PubMed ID: 26961433
[TBL] [Abstract][Full Text] [Related]
11. Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC.
Ou SI; Hong JL; Christopoulos P; Lin HM; Vincent S; Churchill EN; Soeda J; Kazdal D; Stenzinger A; Thomas M
J Thorac Oncol; 2023 Jun; 18(6):744-754. PubMed ID: 36738930
[TBL] [Abstract][Full Text] [Related]
12. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
Yang G; Li J; Xu H; Yang Y; Yang L; Xu F; Xia B; Zhu VW; Nagasaka M; Yang Y; Li Y; Qiu W; Ying J; Ou SI; Wang Y
Lung Cancer; 2020 Jul; 145():186-194. PubMed ID: 32336530
[TBL] [Abstract][Full Text] [Related]
13. Possible False Results With cobas
Kanaoka K; Tamiya A; Inagaki Y; Taniguchi Y; Nakao K; Takeda M; Matsuda Y; Okishio K; Shimizu S
Anticancer Res; 2023 Jun; 43(6):2771-2776. PubMed ID: 37247929
[TBL] [Abstract][Full Text] [Related]
14. Rapid and reliable testing for clinically actionable EGFR mutations in non-small cell lung cancer using the Idylla
Michaelidou K; Karniadakis I; Pantelaion V; Koutoulaki C; Boukla E; Folinas K; Dimaras P; Papadaki MA; Koutsopoulos AV; Mavroudis D; Vourlakou C; Mavridis K; Agelaki S
Expert Rev Mol Diagn; 2024; 24(1-2):89-98. PubMed ID: 38193169
[TBL] [Abstract][Full Text] [Related]
15. Use of the Idylla EGFR Mutation Test for Variant Detection in Non-Small Cell Lung Cancer Samples.
Hawkins P; Stevenson T; Powari M
Am J Clin Pathol; 2021 Sep; 156(4):653-660. PubMed ID: 33877290
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
Papadimitrakopoulou VA; Han JY; Ahn MJ; Ramalingam SS; Delmonte A; Hsia TC; Laskin J; Kim SW; He Y; Tsai CM; Hida T; Maemondo M; Kato T; Jenkins S; Patel S; Huang X; Laus G; Markovets A; Thress KS; Wu YL; Mok T
Cancer; 2020 Jan; 126(2):373-380. PubMed ID: 31769875
[TBL] [Abstract][Full Text] [Related]
17. A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
Yasuda H; Ichihara E; Sakakibara-Konishi J; Zenke Y; Takeuchi S; Morise M; Hotta K; Sato M; Matsumoto S; Tanimoto A; Matsuzawa R; Kiura K; Takashima Y; Yano S; Koyama J; Fukushima T; Hamamoto J; Terai H; Ikemura S; Takemura R; Goto K; Soejima K
Lung Cancer; 2021 Dec; 162():140-146. PubMed ID: 34808485
[TBL] [Abstract][Full Text] [Related]
18. Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy).
de Biase D; Visani M; Malapelle U; Simonato F; Cesari V; Bellevicine C; Pession A; Troncone G; Fassina A; Tallini G
PLoS One; 2013; 8(12):e83607. PubMed ID: 24376723
[TBL] [Abstract][Full Text] [Related]
19. [Chinese Expert Consensus on Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2023 Edition)].
Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee
Zhongguo Fei Ai Za Zhi; 2023 May; 26(5):325-337. PubMed ID: 37316442
[TBL] [Abstract][Full Text] [Related]
20. Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations.
Chen H; Hu S; Patterson AV; Smaill JB; Ding K; Lu X
J Med Chem; 2023 Sep; 66(17):11656-11671. PubMed ID: 37669428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
